相关实验视频
Updated: Apr 30, 2026

11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
8.4K
结合类固醇加5 - 甲注射与放射治疗与单独注射用于状体:一项为期4年的回顾性研究
Beiyi Wu1, Bohan Zhang1, Haitao Xiao2
1Department of Plastic and Burns Surgery, West China Hospital, Sichuan University, 37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, People's Republic of China.
Aesthetic plastic surgery
|May 27, 2025
概括
结合内溶性三氨乙化物 (TAC) + 5-甲 (5-FU) 注射与放射治疗,可显著减少 keloid 复发并改善症状. 这种组合治疗为 keloid 管理提供了比单独注射更好的结果.
科学领域:
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
背景情况:
- 由于高复发率和单一治疗的不令人满意的结果,状体的管理仍然具有挑战性.
- 内注射和放射治疗已成为 keloids 的非手术治疗方法.
- 结合疗法可以通过减轻副作用和治疗负担来提高疗效和患者坚持治疗.
研究的目的:
- 为了评估内伤口三素乙化物 (TAC) +5-甲 (5-FU) 注射与放射治疗相结合的安全性和有效性,与单独内伤口TAC+5-FU注射相比.
- 为了比较治疗组之间的复发率,症状改善和患者自我评估.
主要方法:
- 在2019年至2022年期间,对100名111名 keloid 治疗的患者进行了回顾性评估.
- 数据收集包括基线状况,温哥华痕量表 (VSS) 评分,复发,症状和随访持续时间 (>12个月).
- 患者接受了联合治疗 (注射+放射治疗) 或注射单疗法 (TAC+5-FU).
主要成果:
- 在71名患者的联合治疗中,与29名接受单独注射的患者相比,表现出减少了 keloid 复发率.
- 结合治疗观察到和疼痛等状体症状的显著改善.
- 接受联合治疗的患者报告了更积极的治疗结果,并经历了最小的额外副作用.
结论:
- 内TAC+5-FU注射和放射治疗的结合是治疗 keloid 的有效策略.
- 这种综合方法显著减少了 keloid 复发,并缓解了相关症状.
- 较高的VSS得分和家族病史与增加复发风险有关.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692

